Multiple System Atrophy

Oncology·MeSH: Multiple System Atrophy

Prevalence

5.0 / 100K

6 drugs in development·6 companies·10 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
tak-341	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

Phase 2(2)

Drug	Company
foralumab	Tiziana Life Sciences Ltd (TLSA)
tev-56286	Teva Pharmaceutical Industries Limited (TEVA)

Phase 1(1)

Drug	Company
ion464	IONIS PHARMACEUTICALS INC (IONS)

Unknown(1)

Drug	Company
ath434	Alterity Therapeutics Limited (ATHE)

Phase 2/Phase 3(1)

Drug	Company
tak-341	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

BioSniper tracks 6 drugs in development for Multiple System Atrophy across 6 companies.

There are 10 clinical trials targeting Multiple System Atrophy tracked by BioSniper.

The estimated prevalence of Multiple System Atrophy is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.